New algorithms support Illumina TruPath™ Genome: v4.5 introdues analytical support for TruPath, leveraging algorithmic advances to resolve 15 highly homologous, medically-relevant genes for rare ...
Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...
SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) announced today it has entered into a definitive agreement with Standard BioTools (LAB) under which Illumina will acquire SomaLogic, a ...
Less than two years after Boulder-based biotech firm SomaLogic Inc. merged with Standard BioTools Inc. (Nasdaq: LAB), Illumina Inc. (NASDAQ: ILMN) has inked a deal to absorb SomaLogic’s business in an ...
Illumina Inc. (NASDAQ:ILMN) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Illumina Inc. (NASDAQ:ILMN) is one of the best quality stocks to buy according to hedge funds. On March ...
Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026.
Investors in Illumina Inc (Symbol: ILMN) saw new options become available today, for the June 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ILMN options ...
Hosted on MSN
Illumina (ILMN) Jumps 24.8% on Earnings Beat
We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Illumina, Inc. (NASDAQ:ILMN) is one of the best-performing stocks on Friday. Illumina rallied for a second day on Friday, ...
Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results